Swiss - Delayed Quote CHF
Molecular Partners AG (MOLN.SW)
At close: November 7 at 5:31 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
6,002.00
7,038.00
189,556.00
9,330.00
9,344.00
Operating Expense
69,073.00
68,146.00
72,943.00
72,749.00
67,670.00
Operating Income
-63,071.00
-61,108.00
116,613.00
-63,419.00
-58,326.00
Net Non Operating Interest Income Expense
3,826.00
4,230.00
523.00
-457.00
63.00
Other Income Expense
-3,347.00
-5,106.00
717.00
92.00
-4,512.00
Pretax Income
-62,591.00
-61,984.00
117,853.00
-63,783.00
-62,775.00
Tax Provision
--
--
--
2.00
-11.00
Net Income Common Stockholders
-62,591.00
-61,984.00
117,853.00
-63,785.00
-62,764.00
Diluted NI Available to Com Stockholders
-62,591.00
-61,984.00
117,853.00
-63,785.00
-62,764.00
Basic EPS
-1.75
-1.89
3.63
-2.06
-2.51
Diluted EPS
-1.75
-1.89
3.54
-2.06
-2.51
Basic Average Shares
32,936.14
32,770.67
32,469.96
31,005.17
25,000.65
Diluted Average Shares
32,936.14
32,770.67
33,265.57
31,005.17
25,000.65
Total Operating Income as Reported
-63,071.00
-61,108.00
116,613.00
-63,418.00
-58,326.00
Total Expenses
69,073.00
68,146.00
72,943.00
72,749.00
67,670.00
Net Income from Continuing & Discontinued Operation
-62,591.00
-61,984.00
117,853.00
-63,785.00
-62,764.00
Normalized Income
-59,244.00
-56,878.00
117,136.00
-63,863.26
-58,252.79
Interest Income
3,867.00
4,279.00
1,142.00
99.00
367.00
Interest Expense
27.00
34.00
605.00
548.00
295.00
Net Interest Income
3,826.00
4,230.00
523.00
-457.00
63.00
EBIT
-62,564.00
-61,950.00
118,458.00
-63,235.00
-62,480.00
EBITDA
-60,163.00
-59,530.00
120,846.00
-60,670.00
-59,593.00
Reconciled Depreciation
2,401.00
2,420.00
2,388.00
2,565.00
2,887.00
Net Income from Continuing Operation Net Minority Interest
-62,591.00
-61,984.00
117,853.00
-63,785.00
-62,764.00
Total Unusual Items Excluding Goodwill
-3,347.00
-5,106.00
717.00
92.00
-4,512.00
Total Unusual Items
-3,347.00
-5,106.00
717.00
92.00
-4,512.00
Normalized EBITDA
-56,816.00
-54,424.00
120,129.00
-60,762.00
-55,081.00
Tax Rate for Calcs
--
--
--
0.00
0.00
Tax Effect of Unusual Items
--
--
--
13.74
-0.79
12/31/2020 - 3/3/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
NWRN.SW Newron Pharmaceuticals S.p.A.
7.78
+0.78%
IDIA.SW Idorsia Ltd
0.9600
+4.07%
BSLN.SW Basilea Pharmaceutica AG
42.50
-0.23%
SPEX.SW Spexis AG
0.0570
0.00%
SANN.SW Santhera Pharmaceuticals Holding AG
8.80
+1.27%
EVE.SW Evolva Holding SA
0.8360
-11.06%
NYKD.OL Nykode Therapeutics AS
4.2920
+0.42%
ATORX.ST Alligator Bioscience AB (publ)
0.7220
+9.06%
IVA.PA Inventiva S.A.
2.3950
-1.84%
VVY.AS Vivoryon Therapeutics N.V.
2.1900
-2.88%